Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled and randomly assigned to the experimental group and control group at a 1: 1 ratio.,who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively. Subjects are administered until disease progression assessed by the RECIST V1.1 standard (unless the investigator evaluates that the subject continues to have clinical benefit from continuing treatment, the subject may be allowed to continue treatment), and begins to receive new anti-tumor treatment, unacceptable toxicity, withdrawal of informed consent, or other conditions that meet the criteria for terminating trial treatment / withdrawal from the trial. The research phase of this study is divided into pre-screening period (\~ D-28), screening period (D-28 \~ D-1), treatment period, treatment end visit (± 7 days after the last dose), safety follow-up ( Until 28 ± 7 days after the last dose) and survival follow-up.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzona biopsją rak płaskonabłonkowy przełyku
- •Dobry stan ogólny pacjenta (ECOG 0-1)
- •Oczekiwana długość życia powyżej 3 miesięcy
- •Nowotwór poddany ocenie i dokumentowany u specjalistów
- •Możliwość przełykania leków
- •Prawidłowa funkcja organów wewnętrznych
- •Dobra wola uczestnictwa i zgoda na badanie
✗ Disqualifies
- •Poprzednie leczenie lekami skierowanymi na EGFR lub podobnymi
- •Poprzednie leczenie irinotekanem lub tegafurem
- •Chemioterapia z grupy antracyklin lub mitomycyna w ciągu 6 tygodni
- •Immunoterapia w ciągu 8 tygodni przed badaniem
- •Brak pełnego wyzdrowienia z działań ubocznych wcześniejszych leków
- •Poważna operacja w ciągu 4 tygodni przed badaniem
- •Udział w innym badaniu klinicznym w ciągu 4 tygodni
- •Szczepienie żywą szczepionką w ciągu 28 dni przed badaniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Chinese PLA General Hospital
Beijing, China
Trial contact
JianMing Xu, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/25/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.